General Updates

11th September, 2026 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code:533573 NSE Symbol: APLLTD Dear Sir/Madam, Sub: Successful completion of unannounced USFDA onsite inspection at Alembic Pharmaceuticals Limited’s Bioequivalence Facility in Vadodara, Gujarat We are pleased to inform the stock exchanges that Alembic Pharmaceuticals Limited (‘Company’), has successfully completed an unannounced onsite Bioequivalence inspection conducted by United States Food and Drug Administration (‘USFDA’) at the Company’s Bioequivalence Facility located in Vadodara, Gujarat, with no Form 483 observations. The unannounced onsite USFDA Bioequivalence inspection was conducted from 31st August, 2026 to 10th September, 2026. We request you to kindly take the same on record. Thanking you, Yours faithfully, For Alembic Pharmaceuticals Limited Chirag K. Shukla Company Secretary ALEMBIC PHARMACEUTICALS LIMITED REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. ● TEL: (0265) 2280550, 2280880 ● FAX: (0265) 2281229 Website : www.alembicpharmaceuticals.com ● E-mail : alembic@alembic.co.in ● CIN : L24230GJ2010PLC061123